
zzso high-dose zzso treatment is zzso in acute zzso zzso zzso and attacks of multiple sclerosis zzso The responses to treatment in zzso of patients participating in two randomized, controlled trials were zzso zzso patients with ON and 51 patients with attacks of zzso were treated with zzso or oral zzso zzso zzso daily for five days with a 10-day tapering zzso A zzso zzso magnetic resonance imaging zzso scan was obtained at baseline in 66 patients, and 29 patients underwent repeated zzso zzso zzso patients underwent zzso puncture before zzso The odds ratio zzso of improvement after zzso treatment (a one point change in the visual function system score of the zzso Expanded zzso zzso zzso zzso in ON or in the zzso score in attacks of zzso was higher in patients with enhancing zzso on baseline zzso (one week: OR 15, P zzso zzso eight weeks: OR zzso P zzso zzso zzso treatment suppressed zzso after one week zzso zzso zzso and three weeks zzso zzso zzso zzso fluid measures of zzso inflammation correlated with the area of zzso but did not correlate as closely with the treatment response as did the results of zzso zzso These findings suggest that the resolution of zzso inflammation as assessed by zzso zzso is a major effect of oral high-dose zzso 

